Olmat AMH Tablets (Olmesartan+ Amlodipine+ Hydrochlorothiazide )

• Composition :
  Each tablet contains Olmesartan 20mg / 40mg + Amlodipine 5mg+ Hydochlorothiazide 12.5mg.
• Indications :
  Indicated for the treatment of essential hypertension.
• Pharmacodynamics :
  Olmesartan is a selective angiotensin II receptor antagonist. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in the vascular smooth muscle. Amlodipine is a calcium ion influx inhibitor of the dihydropiridine group and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. The antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, leading to reductions in peripheral vascular resistance and blood pressure. Hydrochlorothiazide blocks the reabsorption of sodium and chloride ions, and it thereby increases the quantity of sodium traversing the distal tubule and the volume of water excreted.
• Dosage and administration :
  One tablet once daily.Dosage may be increased after 2 weeks to a maximum dose of 40 /10 /25 mg once daily, usually by increasing one component at a time
• Contraindications :
  Contraindicated in patients with anuria and in patients withknown hypersensitivity to any active ingredients or any other component of this product.
• Precautions and warnings :
  Hypotension in volume- or salt-depleted patients with treatment initiation may occur. Correct volumedepletion prior to administration.Increased angina or myocardial infarction with calcium channel blockers may occur upon dosage initiation or increase. Withhold or discontinue olmesartan medoxomil, amlodipine and hydrochlorothiazide if progressive renal impairment becomes evident. Avoid in patients with severely impaired hepatic function. Observe for signs of fluid or electrolyte imbalance. Use with caution in patients with untreated angle closure glaucoma.
• Use in pregnancy, lactation & pediatrics :
  Fetal toxicity:Pregnancy Category D. Avoid use in pregnancyIt is not known whether olmesartan is excreted in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.The safety and effectiveness of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in pediatric patients have not been established.
• Drug interactions :
  Olmesartan used concomitantly with NSAIDs use may lead to increased risk of renal impairment and loss of antihypertensive effect. Amlodipine-Strong inhibitors of CYP3A4(e.g. ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of amlodipine to a greater extent. Amlodipine increases the exposure of cyclosporine and tacrolimus. Hydrochlorothiazide- Lithium: The renal clearance of lithium is reduced by thiazides and consequently the risk of lithium toxicity may be increased, dosage adjustment of the antidiabetic drug may be required, if used concomitantly. NSAIDs may reduce the diuretic, natriuretic, and antihypertensive effects of Hydrochlorothiazide.Alcohol, barbiturates, narcotics-Potentiate orthostatic hypotension.
• Adverse reactions :
  Dizziness, peripheral edema, headache, fatigue, nasopharyngitis, muscle spasms, nausea, diarrheaand joint swelling.
• Therapy Area :
  Anti-Hypertensives